BioRestorative Therapies, Inc. announced a public offering of 14,285,715 shares of common stock at $0.35 per share, with accompanying warrants. The offering is expected to raise approximately $5.0 million for the Company. The funds will be used for clinical trials, research, development, and other corporate purposes. The offering is expected to close on February 13, 2026. The Company focuses on stem cell-based therapies, with programs targeting disc/spine disease, metabolic disorders, and a commercial BioCosmeceutical platform.

The Company’s lead candidate, BRTX-100, utilizes mesenchymal stem cells for non-surgical treatment of disc disorders. Another program, ThermoStem, targets obesity and metabolic disorders using brown adipose derived stem cells. The Company also operates a commercial BioCosmeceutical platform, offering products to reduce fine lines and wrinkles. Forward-looking statements caution investors of potential risks and uncertainties. For further information, contact Stephen Kilmer, Investor Relations at [email protected].

Read more at GlobeNewswire: BioRestorative Announces Pricing of $5.0 Million Public